Review





Similar Products

99
New England Biolabs large klenow
Large Klenow, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/DNA+Pol+I+Klenow+Fragment/pmc13750608-183-9-11
Average 99 stars, based on 1 article reviews
large klenow - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

95
Zymo Research zymoclean large fragment dna recovery kit
Zymoclean Large Fragment Dna Recovery Kit, supplied by Zymo Research, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/Zymoclean+Large+Fragment+DNA+Recovery/pmc13733432-786-18-24
Average 95 stars, based on 1 article reviews
zymoclean large fragment dna recovery kit - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

97
ChemoMetec dna fragmentation
Treatment of MDA-MB-231 cells with KMR and KM75 induced fragmentation of DNA. MDA-MB-231 cells were treated with KMR (0.1, 0.2, and 0.3 mg mL −1 ), KM75 (0.05, 0.1, and 0.2 mg mL −1 ), 0.3% DMSO vehicle control (VC), and Cisplatin (0.03 mg mL −1 ) as a positive control for 24 h and percentage cells with fragmented DNA measured (Top panel). Control and treated cells were stained by DAPI, imaged and quantified by using NucleoCounter® <t>NC-3000™</t> (Bottom Panel). The percentage of cells exhibiting fragmented DNA was quantified. Data are presented as mean ± SD from three independent experiments ( n = 3). Error bars represent standard deviation (SD). Statistical significance was analyzed using repeated-measures one-way ANOVA, followed by Dunnett's multiple-comparisons test, with each experimental group compared with the vehicle control. Exact p values are indicated above the respective comparison brackets. Asterisks denote statistical significance ( P < 0.05), whereas “ns” indicates a non-significant difference ( P ≥ 0.05). Representative cell-distribution plots and DNA-intensity histograms for untreated, vehicle control, cisplatin, KMR, and KM75-treated cells are shown below the quantitative analysis.
Dna Fragmentation, supplied by ChemoMetec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/NucleoCounter+NC-3000/pmc13760499-168-0-10
Average 97 stars, based on 1 article reviews
dna fragmentation - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

99
New England Biolabs klenow fragment
Treatment of MDA-MB-231 cells with KMR and KM75 induced fragmentation of DNA. MDA-MB-231 cells were treated with KMR (0.1, 0.2, and 0.3 mg mL −1 ), KM75 (0.05, 0.1, and 0.2 mg mL −1 ), 0.3% DMSO vehicle control (VC), and Cisplatin (0.03 mg mL −1 ) as a positive control for 24 h and percentage cells with fragmented DNA measured (Top panel). Control and treated cells were stained by DAPI, imaged and quantified by using NucleoCounter® <t>NC-3000™</t> (Bottom Panel). The percentage of cells exhibiting fragmented DNA was quantified. Data are presented as mean ± SD from three independent experiments ( n = 3). Error bars represent standard deviation (SD). Statistical significance was analyzed using repeated-measures one-way ANOVA, followed by Dunnett's multiple-comparisons test, with each experimental group compared with the vehicle control. Exact p values are indicated above the respective comparison brackets. Asterisks denote statistical significance ( P < 0.05), whereas “ns” indicates a non-significant difference ( P ≥ 0.05). Representative cell-distribution plots and DNA-intensity histograms for untreated, vehicle control, cisplatin, KMR, and KM75-treated cells are shown below the quantitative analysis.
Klenow Fragment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/DNA+Pol+I+Klenow+Fragment/bio_rxiv__64898__2026__11__06__764689-76-13-16
Average 99 stars, based on 1 article reviews
klenow fragment - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
New England Biolabs large klenow fragment dna polymerase
Treatment of MDA-MB-231 cells with KMR and KM75 induced fragmentation of DNA. MDA-MB-231 cells were treated with KMR (0.1, 0.2, and 0.3 mg mL −1 ), KM75 (0.05, 0.1, and 0.2 mg mL −1 ), 0.3% DMSO vehicle control (VC), and Cisplatin (0.03 mg mL −1 ) as a positive control for 24 h and percentage cells with fragmented DNA measured (Top panel). Control and treated cells were stained by DAPI, imaged and quantified by using NucleoCounter® <t>NC-3000™</t> (Bottom Panel). The percentage of cells exhibiting fragmented DNA was quantified. Data are presented as mean ± SD from three independent experiments ( n = 3). Error bars represent standard deviation (SD). Statistical significance was analyzed using repeated-measures one-way ANOVA, followed by Dunnett's multiple-comparisons test, with each experimental group compared with the vehicle control. Exact p values are indicated above the respective comparison brackets. Asterisks denote statistical significance ( P < 0.05), whereas “ns” indicates a non-significant difference ( P ≥ 0.05). Representative cell-distribution plots and DNA-intensity histograms for untreated, vehicle control, cisplatin, KMR, and KM75-treated cells are shown below the quantitative analysis.
Large Klenow Fragment Dna Polymerase, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/Klenow+Fragment/bio_rxiv__64898__2026__11__05__764102-156-52-59
Average 99 stars, based on 1 article reviews
large klenow fragment dna polymerase - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

95
New England Biolabs bsu dna polymerase large fragment
Treatment of MDA-MB-231 cells with KMR and KM75 induced fragmentation of DNA. MDA-MB-231 cells were treated with KMR (0.1, 0.2, and 0.3 mg mL −1 ), KM75 (0.05, 0.1, and 0.2 mg mL −1 ), 0.3% DMSO vehicle control (VC), and Cisplatin (0.03 mg mL −1 ) as a positive control for 24 h and percentage cells with fragmented DNA measured (Top panel). Control and treated cells were stained by DAPI, imaged and quantified by using NucleoCounter® <t>NC-3000™</t> (Bottom Panel). The percentage of cells exhibiting fragmented DNA was quantified. Data are presented as mean ± SD from three independent experiments ( n = 3). Error bars represent standard deviation (SD). Statistical significance was analyzed using repeated-measures one-way ANOVA, followed by Dunnett's multiple-comparisons test, with each experimental group compared with the vehicle control. Exact p values are indicated above the respective comparison brackets. Asterisks denote statistical significance ( P < 0.05), whereas “ns” indicates a non-significant difference ( P ≥ 0.05). Representative cell-distribution plots and DNA-intensity histograms for untreated, vehicle control, cisplatin, KMR, and KM75-treated cells are shown below the quantitative analysis.
Bsu Dna Polymerase Large Fragment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/Bsu+DNA+Polymerase%2C+Large+Fragment/pm42995254-339-89-95
Average 95 stars, based on 1 article reviews
bsu dna polymerase large fragment - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

99
Illumina Inc transposon mediated fragmentation
Treatment of MDA-MB-231 cells with KMR and KM75 induced fragmentation of DNA. MDA-MB-231 cells were treated with KMR (0.1, 0.2, and 0.3 mg mL −1 ), KM75 (0.05, 0.1, and 0.2 mg mL −1 ), 0.3% DMSO vehicle control (VC), and Cisplatin (0.03 mg mL −1 ) as a positive control for 24 h and percentage cells with fragmented DNA measured (Top panel). Control and treated cells were stained by DAPI, imaged and quantified by using NucleoCounter® <t>NC-3000™</t> (Bottom Panel). The percentage of cells exhibiting fragmented DNA was quantified. Data are presented as mean ± SD from three independent experiments ( n = 3). Error bars represent standard deviation (SD). Statistical significance was analyzed using repeated-measures one-way ANOVA, followed by Dunnett's multiple-comparisons test, with each experimental group compared with the vehicle control. Exact p values are indicated above the respective comparison brackets. Asterisks denote statistical significance ( P < 0.05), whereas “ns” indicates a non-significant difference ( P ≥ 0.05). Representative cell-distribution plots and DNA-intensity histograms for untreated, vehicle control, cisplatin, KMR, and KM75-treated cells are shown below the quantitative analysis.
Transposon Mediated Fragmentation, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/Nextera+XT+DNA+Library+Preparation+Kit/bio_rxiv__64898__2026__10__29__762796-363-8-12
Average 99 stars, based on 1 article reviews
transposon mediated fragmentation - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
New England Biolabs dna polymerase i large klenow fragment
Treatment of MDA-MB-231 cells with KMR and KM75 induced fragmentation of DNA. MDA-MB-231 cells were treated with KMR (0.1, 0.2, and 0.3 mg mL −1 ), KM75 (0.05, 0.1, and 0.2 mg mL −1 ), 0.3% DMSO vehicle control (VC), and Cisplatin (0.03 mg mL −1 ) as a positive control for 24 h and percentage cells with fragmented DNA measured (Top panel). Control and treated cells were stained by DAPI, imaged and quantified by using NucleoCounter® <t>NC-3000™</t> (Bottom Panel). The percentage of cells exhibiting fragmented DNA was quantified. Data are presented as mean ± SD from three independent experiments ( n = 3). Error bars represent standard deviation (SD). Statistical significance was analyzed using repeated-measures one-way ANOVA, followed by Dunnett's multiple-comparisons test, with each experimental group compared with the vehicle control. Exact p values are indicated above the respective comparison brackets. Asterisks denote statistical significance ( P < 0.05), whereas “ns” indicates a non-significant difference ( P ≥ 0.05). Representative cell-distribution plots and DNA-intensity histograms for untreated, vehicle control, cisplatin, KMR, and KM75-treated cells are shown below the quantitative analysis.
Dna Polymerase I Large Klenow Fragment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/T4+DNA+Ligase/pm42972103-429-116-122
Average 99 stars, based on 1 article reviews
dna polymerase i large klenow fragment - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

93
Addgene inc dna fragment
<t>G6PD</t> 2-hydroxyisobutyrylation sites, selection of pWT and expression of G6PD variants. A. Structure of inactive D200N human G6PD monomer (PDB ID: 7SNI) . The nine lysine 2-hydroxyisobutyrylation sites selected for this study are shown as sticks and highlighted in red. The dimer and tetramer interfaces are marked schematically by a continuous and a dashed line, respectively. Structural NADP + and the substrates G6P and NADP + are also shown. B. Validation of HibK414 G6PD as a non-2-hydroxyisobutyrylated control. Immunoblots show the modification level (anti-HibK or anti-AcK) of Flag-tagged G6PD variants expressed in cultured HEK293T cells. Immunoblot intensities of N414(HibK414) and Q83(HibK83) are displayed relative to the published control (AcK414) . C. HibK-dependent incorporation and expression of G6PD variants in mammalian cells. Cleared total lysates of HEK293T cells expressing the indicated G6PD variant, or the shRNA alone (sh) as a control, and cultured in the absence (-) or presence (+) of HibK, were resolved by SDS-PAGE. Immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK), expression of full-length G6PD-Flag (anti-Flag), and expression of full-length and C-truncated G6PD (anti-G6PD). D. De-2-hydroxyisobutyrylation of G6PD variants by endogenous KDACs. Flag-tagged G6PD was immunoprecipitated from HEK293T cells expressing WT, pWT, or the indicated 2-hydroxyisobutyrylated variant, cultured without (-) or with (+) KDACi. Immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK) and the amount of full-length G6PD loaded in each lane (anti-Flag).
Dna Fragment, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/G6PD%2FpRK5+(Plasmid+%2341521)/bio_rxiv__64898__2026__10__29__762733-251-2-11
Average 93 stars, based on 1 article reviews
dna fragment - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

96
TaKaRa minibest dna fragment purification kit v4 0
<t>G6PD</t> 2-hydroxyisobutyrylation sites, selection of pWT and expression of G6PD variants. A. Structure of inactive D200N human G6PD monomer (PDB ID: 7SNI) . The nine lysine 2-hydroxyisobutyrylation sites selected for this study are shown as sticks and highlighted in red. The dimer and tetramer interfaces are marked schematically by a continuous and a dashed line, respectively. Structural NADP + and the substrates G6P and NADP + are also shown. B. Validation of HibK414 G6PD as a non-2-hydroxyisobutyrylated control. Immunoblots show the modification level (anti-HibK or anti-AcK) of Flag-tagged G6PD variants expressed in cultured HEK293T cells. Immunoblot intensities of N414(HibK414) and Q83(HibK83) are displayed relative to the published control (AcK414) . C. HibK-dependent incorporation and expression of G6PD variants in mammalian cells. Cleared total lysates of HEK293T cells expressing the indicated G6PD variant, or the shRNA alone (sh) as a control, and cultured in the absence (-) or presence (+) of HibK, were resolved by SDS-PAGE. Immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK), expression of full-length G6PD-Flag (anti-Flag), and expression of full-length and C-truncated G6PD (anti-G6PD). D. De-2-hydroxyisobutyrylation of G6PD variants by endogenous KDACs. Flag-tagged G6PD was immunoprecipitated from HEK293T cells expressing WT, pWT, or the indicated 2-hydroxyisobutyrylated variant, cultured without (-) or with (+) KDACi. Immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK) and the amount of full-length G6PD loaded in each lane (anti-Flag).
Minibest Dna Fragment Purification Kit V4 0, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dna+fragments/TaKaRa+MiniBEST+DNA+Fragment+Purification+Kit+Ver%2E4%2E0/bio_rxiv__64898__2026__10__26__762064-222-5-11
Average 96 stars, based on 1 article reviews
minibest dna fragment purification kit v4 0 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


Treatment of MDA-MB-231 cells with KMR and KM75 induced fragmentation of DNA. MDA-MB-231 cells were treated with KMR (0.1, 0.2, and 0.3 mg mL −1 ), KM75 (0.05, 0.1, and 0.2 mg mL −1 ), 0.3% DMSO vehicle control (VC), and Cisplatin (0.03 mg mL −1 ) as a positive control for 24 h and percentage cells with fragmented DNA measured (Top panel). Control and treated cells were stained by DAPI, imaged and quantified by using NucleoCounter® NC-3000™ (Bottom Panel). The percentage of cells exhibiting fragmented DNA was quantified. Data are presented as mean ± SD from three independent experiments ( n = 3). Error bars represent standard deviation (SD). Statistical significance was analyzed using repeated-measures one-way ANOVA, followed by Dunnett's multiple-comparisons test, with each experimental group compared with the vehicle control. Exact p values are indicated above the respective comparison brackets. Asterisks denote statistical significance ( P < 0.05), whereas “ns” indicates a non-significant difference ( P ≥ 0.05). Representative cell-distribution plots and DNA-intensity histograms for untreated, vehicle control, cisplatin, KMR, and KM75-treated cells are shown below the quantitative analysis.

Journal: RSC Advances

Article Title: Phytochemical-rich fraction from raw and cooked kodo millet ( Paspalum scrobiculatum L.) reduced the viability of colorectal- and breast cancer cells in vitro by inducing apoptosis

doi: 10.1039/d6ra05280k

Figure Lengend Snippet: Treatment of MDA-MB-231 cells with KMR and KM75 induced fragmentation of DNA. MDA-MB-231 cells were treated with KMR (0.1, 0.2, and 0.3 mg mL −1 ), KM75 (0.05, 0.1, and 0.2 mg mL −1 ), 0.3% DMSO vehicle control (VC), and Cisplatin (0.03 mg mL −1 ) as a positive control for 24 h and percentage cells with fragmented DNA measured (Top panel). Control and treated cells were stained by DAPI, imaged and quantified by using NucleoCounter® NC-3000™ (Bottom Panel). The percentage of cells exhibiting fragmented DNA was quantified. Data are presented as mean ± SD from three independent experiments ( n = 3). Error bars represent standard deviation (SD). Statistical significance was analyzed using repeated-measures one-way ANOVA, followed by Dunnett's multiple-comparisons test, with each experimental group compared with the vehicle control. Exact p values are indicated above the respective comparison brackets. Asterisks denote statistical significance ( P < 0.05), whereas “ns” indicates a non-significant difference ( P ≥ 0.05). Representative cell-distribution plots and DNA-intensity histograms for untreated, vehicle control, cisplatin, KMR, and KM75-treated cells are shown below the quantitative analysis.

Article Snippet: DNA fragmentation was assessed using the NucleoCounter NC-3000 image cytometer (ChemoMetec A/S, Denmark) according to the manufacturer's DNA Fragmentation Assay protocol.

Techniques: Control, Positive Control, Staining, Standard Deviation, Comparison, Analysis, DNA Fragmentation Assay

G6PD 2-hydroxyisobutyrylation sites, selection of pWT and expression of G6PD variants. A. Structure of inactive D200N human G6PD monomer (PDB ID: 7SNI) . The nine lysine 2-hydroxyisobutyrylation sites selected for this study are shown as sticks and highlighted in red. The dimer and tetramer interfaces are marked schematically by a continuous and a dashed line, respectively. Structural NADP + and the substrates G6P and NADP + are also shown. B. Validation of HibK414 G6PD as a non-2-hydroxyisobutyrylated control. Immunoblots show the modification level (anti-HibK or anti-AcK) of Flag-tagged G6PD variants expressed in cultured HEK293T cells. Immunoblot intensities of N414(HibK414) and Q83(HibK83) are displayed relative to the published control (AcK414) . C. HibK-dependent incorporation and expression of G6PD variants in mammalian cells. Cleared total lysates of HEK293T cells expressing the indicated G6PD variant, or the shRNA alone (sh) as a control, and cultured in the absence (-) or presence (+) of HibK, were resolved by SDS-PAGE. Immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK), expression of full-length G6PD-Flag (anti-Flag), and expression of full-length and C-truncated G6PD (anti-G6PD). D. De-2-hydroxyisobutyrylation of G6PD variants by endogenous KDACs. Flag-tagged G6PD was immunoprecipitated from HEK293T cells expressing WT, pWT, or the indicated 2-hydroxyisobutyrylated variant, cultured without (-) or with (+) KDACi. Immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK) and the amount of full-length G6PD loaded in each lane (anti-Flag).

Journal: bioRxiv

Article Title: One lysine, two acyl marks: 2-hydroxyisobutyrylation and acetylation of G6PD differ in outcome and regulation

doi: 10.64898/2026.10.29.762733

Figure Lengend Snippet: G6PD 2-hydroxyisobutyrylation sites, selection of pWT and expression of G6PD variants. A. Structure of inactive D200N human G6PD monomer (PDB ID: 7SNI) . The nine lysine 2-hydroxyisobutyrylation sites selected for this study are shown as sticks and highlighted in red. The dimer and tetramer interfaces are marked schematically by a continuous and a dashed line, respectively. Structural NADP + and the substrates G6P and NADP + are also shown. B. Validation of HibK414 G6PD as a non-2-hydroxyisobutyrylated control. Immunoblots show the modification level (anti-HibK or anti-AcK) of Flag-tagged G6PD variants expressed in cultured HEK293T cells. Immunoblot intensities of N414(HibK414) and Q83(HibK83) are displayed relative to the published control (AcK414) . C. HibK-dependent incorporation and expression of G6PD variants in mammalian cells. Cleared total lysates of HEK293T cells expressing the indicated G6PD variant, or the shRNA alone (sh) as a control, and cultured in the absence (-) or presence (+) of HibK, were resolved by SDS-PAGE. Immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK), expression of full-length G6PD-Flag (anti-Flag), and expression of full-length and C-truncated G6PD (anti-G6PD). D. De-2-hydroxyisobutyrylation of G6PD variants by endogenous KDACs. Flag-tagged G6PD was immunoprecipitated from HEK293T cells expressing WT, pWT, or the indicated 2-hydroxyisobutyrylated variant, cultured without (-) or with (+) KDACi. Immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK) and the amount of full-length G6PD loaded in each lane (anti-Flag).

Article Snippet: Briefly, the DNA fragment encoding human G6PD (Gift from Xiaolu Yang Addgene plasmid # 41521; http://n2t.net/addgene:41521 ) with a C-terminal 6 × His tag was subcloned into a pCDF-Duet1 plasmid that contains the U25C mutant of PylT under the control of a constitutive lpp promoter .

Techniques: Selection, Expressing, Biomarker Discovery, Control, Western Blot, Modification, Cell Culture, Variant Assay, shRNA, SDS Page, Immunoprecipitation

Regulation of G6PD activity and oligomerization by 2-hydroxyisobutyrylation. A., B. Activity of G6PD-Flag variants expressed in HEK293T cells cultured in the absence (A) or presence (B) of KDACi. Bars represent the V max of exogenous G6PD measured in cleared cell lysates, normalized to immunoblot intensities of G6PD expression and displayed relative to pWT. C. Native PAGE analysis of G6PD variants expressed in HEK293T cells. Bars represent the ratio between the higher-order oligomeric species and total G6PD, determined by immunoblot quantification. Data are the mean ± SD; n ≥ 4 biological replicates. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test.

Journal: bioRxiv

Article Title: One lysine, two acyl marks: 2-hydroxyisobutyrylation and acetylation of G6PD differ in outcome and regulation

doi: 10.64898/2026.10.29.762733

Figure Lengend Snippet: Regulation of G6PD activity and oligomerization by 2-hydroxyisobutyrylation. A., B. Activity of G6PD-Flag variants expressed in HEK293T cells cultured in the absence (A) or presence (B) of KDACi. Bars represent the V max of exogenous G6PD measured in cleared cell lysates, normalized to immunoblot intensities of G6PD expression and displayed relative to pWT. C. Native PAGE analysis of G6PD variants expressed in HEK293T cells. Bars represent the ratio between the higher-order oligomeric species and total G6PD, determined by immunoblot quantification. Data are the mean ± SD; n ≥ 4 biological replicates. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test.

Article Snippet: Briefly, the DNA fragment encoding human G6PD (Gift from Xiaolu Yang Addgene plasmid # 41521; http://n2t.net/addgene:41521 ) with a C-terminal 6 × His tag was subcloned into a pCDF-Duet1 plasmid that contains the U25C mutant of PylT under the control of a constitutive lpp promoter .

Techniques: Activity Assay, Cell Culture, Western Blot, Expressing, Clear Native PAGE, Analysis

Acylation of K386 modulates G6PD stability and enzyme kinetics. A. Residual activity of WT and K386-modified G6PD after heat inactivation. The indicated G6PD variants, expressed in cultured HEK293T cells (top) or expressed recombinantly in bacteria and purified (bottom), were incubated at increasing temperatures before measurement of G6PD activity. Graphs show the residual activity as a function of incubation temperature, together with the fit of the data to a four-parameter logistic function (red line) from which T 1 / 2 values were calculated. T 1 / 2 values are reported ± fitting error; n = 3. N.D., not determined. B. Residual activity of G6PD variants at physiologically relevant temperatures. Bars represent the activity of the indicated purified G6PD variants before and after overnight incubation at 25°C or 37°C, normalized to the activity of WT G6PD prior to incubation. Data are the mean ± SD; n = 3. C. Limited proteolysis as a measure of conformational stability. Purified G6PD variants were incubated with chymotrypsin for the indicated times, and proteolytic degradation was monitored by SDS-PAGE and Coomassie staining. The persistence of the intact protein over time was used as a measure of resistance to proteolysis and, consequently, of conformational stability. D. Apparent Michaelis constants ( K M app ) for G6P and NADP + . The steady-state kinetics of WT and K386-modified G6PD were measured as a function of G6P or NADP concentration, and initial rates were fitted to the Michaelis–Menten equation, from which K M app values were extracted. Bars represent the mean ± SD; n = 3 independent measurements. E. Apparent maximal velocities ( V max app ) of WT and K386-modified G6PD. Steady-state kinetics were measured and V max app values were extracted as described in panel D. Bars represent the mean ± SD; n = 6 independent measurements. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test (B, D & E).

Journal: bioRxiv

Article Title: One lysine, two acyl marks: 2-hydroxyisobutyrylation and acetylation of G6PD differ in outcome and regulation

doi: 10.64898/2026.10.29.762733

Figure Lengend Snippet: Acylation of K386 modulates G6PD stability and enzyme kinetics. A. Residual activity of WT and K386-modified G6PD after heat inactivation. The indicated G6PD variants, expressed in cultured HEK293T cells (top) or expressed recombinantly in bacteria and purified (bottom), were incubated at increasing temperatures before measurement of G6PD activity. Graphs show the residual activity as a function of incubation temperature, together with the fit of the data to a four-parameter logistic function (red line) from which T 1 / 2 values were calculated. T 1 / 2 values are reported ± fitting error; n = 3. N.D., not determined. B. Residual activity of G6PD variants at physiologically relevant temperatures. Bars represent the activity of the indicated purified G6PD variants before and after overnight incubation at 25°C or 37°C, normalized to the activity of WT G6PD prior to incubation. Data are the mean ± SD; n = 3. C. Limited proteolysis as a measure of conformational stability. Purified G6PD variants were incubated with chymotrypsin for the indicated times, and proteolytic degradation was monitored by SDS-PAGE and Coomassie staining. The persistence of the intact protein over time was used as a measure of resistance to proteolysis and, consequently, of conformational stability. D. Apparent Michaelis constants ( K M app ) for G6P and NADP + . The steady-state kinetics of WT and K386-modified G6PD were measured as a function of G6P or NADP concentration, and initial rates were fitted to the Michaelis–Menten equation, from which K M app values were extracted. Bars represent the mean ± SD; n = 3 independent measurements. E. Apparent maximal velocities ( V max app ) of WT and K386-modified G6PD. Steady-state kinetics were measured and V max app values were extracted as described in panel D. Bars represent the mean ± SD; n = 6 independent measurements. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test (B, D & E).

Article Snippet: Briefly, the DNA fragment encoding human G6PD (Gift from Xiaolu Yang Addgene plasmid # 41521; http://n2t.net/addgene:41521 ) with a C-terminal 6 × His tag was subcloned into a pCDF-Duet1 plasmid that contains the U25C mutant of PylT under the control of a constitutive lpp promoter .

Techniques: Stability, Enzymatic Assay, Activity Assay, Modification, Inactivation, Cell Culture, Bacteria, Purification, Incubation, SDS Page, Coomassie Staining, Concentration Assay, Analysis

2-hydroxyisobutyrylation of G6PD at K386 weakens polar interactions across the tetramer interface. A. Schematic representation of the G6PD tetramer, composed of chains A and B (dimer 1) and chains C and D (dimer 2). Each protomer contains one catalytic G6P site, one catalytic NADP + site, and one structural NADP + binding site. The tetramer interface is marked schematically by a dotted vertical line, and the dimer interface by a solid horizontal line. B. Average number of protein-protein H-bonds in tetrameric G6PD. Bars represent the mean ± SD of three independent replicates, for the total number of protein-protein H-bonds and for the individual H-bond sub-types. C. Average number of salt bridges formed across the tetramer interface. Bars represent the mean ± SD; n = 3 independent replicates. D. Average number of polar interactions between selected residue pairs across the tetramer interface. Bars represent the mean ± SD; n = 3 independent replicates. E. Superposition of WT (dark gray) and HibK386 (steel blue) G6PD, with key residue pairs at the tetramer interface rendered as sticks and polar interactions found only in WT G6PD marked by a dashed line. The focused views highlight residue pairs D283/D286–K290, K275–E347, and D228—R227. Statistical analysis was performed using a t-test (C & D).

Journal: bioRxiv

Article Title: One lysine, two acyl marks: 2-hydroxyisobutyrylation and acetylation of G6PD differ in outcome and regulation

doi: 10.64898/2026.10.29.762733

Figure Lengend Snippet: 2-hydroxyisobutyrylation of G6PD at K386 weakens polar interactions across the tetramer interface. A. Schematic representation of the G6PD tetramer, composed of chains A and B (dimer 1) and chains C and D (dimer 2). Each protomer contains one catalytic G6P site, one catalytic NADP + site, and one structural NADP + binding site. The tetramer interface is marked schematically by a dotted vertical line, and the dimer interface by a solid horizontal line. B. Average number of protein-protein H-bonds in tetrameric G6PD. Bars represent the mean ± SD of three independent replicates, for the total number of protein-protein H-bonds and for the individual H-bond sub-types. C. Average number of salt bridges formed across the tetramer interface. Bars represent the mean ± SD; n = 3 independent replicates. D. Average number of polar interactions between selected residue pairs across the tetramer interface. Bars represent the mean ± SD; n = 3 independent replicates. E. Superposition of WT (dark gray) and HibK386 (steel blue) G6PD, with key residue pairs at the tetramer interface rendered as sticks and polar interactions found only in WT G6PD marked by a dashed line. The focused views highlight residue pairs D283/D286–K290, K275–E347, and D228—R227. Statistical analysis was performed using a t-test (C & D).

Article Snippet: Briefly, the DNA fragment encoding human G6PD (Gift from Xiaolu Yang Addgene plasmid # 41521; http://n2t.net/addgene:41521 ) with a C-terminal 6 × His tag was subcloned into a pCDF-Duet1 plasmid that contains the U25C mutant of PylT under the control of a constitutive lpp promoter .

Techniques: Binding Assay, Residue, Analysis

SIRT2 mediates G6PD de-2-hydroxyisobutyrylation and reactivation. A. de-2-hydroxyisobutyrylation of HibK386 G6PD by human sirtuins in bacteria. HibK386 G6PD was co-expressed in bacteria with SIRT1–7, and K386 2-hydroxyisobutyrylation (anti-HibK) and G6PD expression levels (anti-His) were assessed by Western blotting. Levels of K386 2-hydroxyisobutyrylation were calculated from anti-HibK immunoblot intensity relative to protein expression level, and normalized to 2-hydroxyisobutyrylation levels of HibK386 expressed in bacteria co-transformed with an empty vector. Bars represent the mean ± SD; n ≥ 4. B. SIRT2-mediated de-2-hydroxyisobutyrylation of HibK386 G6PD in bacteria. The de-2-hydroxyisobutyrylation activity of SIRT2 was assessed as described in panel A. Bacteria were cultured in the absence (-) or presence (+) of the sirtuin inhibitor NAM. Bars represent the mean ± SD; n = 3. C. SIRT2-mediated de-2-hydroxyisobutyrylation of HibK386 G6PD in mammalian cells. Representative immunoblots show K386 2-hydroxyisobutyrylation levels (anti-HibK) and total amount of G6PD (anti-Flag), following co-expression with SIRT2 in HEK293T cells and immunoprecipitation with anti-Flag antibodies. Levels of K386 2-hydroxyisobutyrylation were calculated from anti-HibK immunoblot intensity relative to protein amount, and normalized to the 2-hydroxyisobutyrylation level of HibK386 G6PD expressed in cells co-transfected with an empty vector. Bars represent the mean ± SD; n = 4. D. SIRT2-mediated de-2-hydroxyisobutyrylation of HibK386 G6PD in vitro. Representative immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK) and the amount of purified HibK386 G6PD (anti-His) following incubation without or with purified SIRT2. Levels of K386 2-hydroxyisobutyrylation were calculated from anti-HibK immunoblot intensity relative to protein amount, and normalized to HibK386 G6PD incubated without SIRT2. Bars represent the mean ± SD; n = 3. E. SIRT2 reactivates HibK386 G6PD. WT or HibK386 G6PD were co-expressed with SIRT2 in bacteria, as described in panel A. The activity of purified G6PD was measured under V max conditions and normalized to the activity of WT G6PD expressed in bacteria co-transformed with an empty vector. Bars represent the mean ± SD; n = 6. F. SIRT2-mediated de-2-hydroxyisobutyrylation of HibK288 G6PD in bacteria. The de-2-hydroxyisobutyrylation activity of SIRT2 was assessed as described in panel A. Bars represent the mean ± SD; n = 3. G. HibK62 PKM2 is a substrate of SIRT2. PKM2 was co-expressed with SIRT2 in bacteria, and 2-hydroxyisobutyrylation levels were evaluated as described in panel A. Values are displayed relative to the 2-hydroxyisobutyrylation level of PKM2 expressed in bacteria co-transformed with an empty vector. Bars represent the mean ± SD; n = 3. H, I. SIRT1- and SIRT2-mediated deacetylation of AcK386 G6PD in bacteria (H) and mammalian cells (I). Levels of K386 acetylation were determined using anti-AcK antibody as described in panels A and C. Bars represent the mean ± SD; n = 3. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test (A, B, E, G, H, and I) or t-test (C, D & F).

Journal: bioRxiv

Article Title: One lysine, two acyl marks: 2-hydroxyisobutyrylation and acetylation of G6PD differ in outcome and regulation

doi: 10.64898/2026.10.29.762733

Figure Lengend Snippet: SIRT2 mediates G6PD de-2-hydroxyisobutyrylation and reactivation. A. de-2-hydroxyisobutyrylation of HibK386 G6PD by human sirtuins in bacteria. HibK386 G6PD was co-expressed in bacteria with SIRT1–7, and K386 2-hydroxyisobutyrylation (anti-HibK) and G6PD expression levels (anti-His) were assessed by Western blotting. Levels of K386 2-hydroxyisobutyrylation were calculated from anti-HibK immunoblot intensity relative to protein expression level, and normalized to 2-hydroxyisobutyrylation levels of HibK386 expressed in bacteria co-transformed with an empty vector. Bars represent the mean ± SD; n ≥ 4. B. SIRT2-mediated de-2-hydroxyisobutyrylation of HibK386 G6PD in bacteria. The de-2-hydroxyisobutyrylation activity of SIRT2 was assessed as described in panel A. Bacteria were cultured in the absence (-) or presence (+) of the sirtuin inhibitor NAM. Bars represent the mean ± SD; n = 3. C. SIRT2-mediated de-2-hydroxyisobutyrylation of HibK386 G6PD in mammalian cells. Representative immunoblots show K386 2-hydroxyisobutyrylation levels (anti-HibK) and total amount of G6PD (anti-Flag), following co-expression with SIRT2 in HEK293T cells and immunoprecipitation with anti-Flag antibodies. Levels of K386 2-hydroxyisobutyrylation were calculated from anti-HibK immunoblot intensity relative to protein amount, and normalized to the 2-hydroxyisobutyrylation level of HibK386 G6PD expressed in cells co-transfected with an empty vector. Bars represent the mean ± SD; n = 4. D. SIRT2-mediated de-2-hydroxyisobutyrylation of HibK386 G6PD in vitro. Representative immunoblots show 2-hydroxyisobutyrylation levels (anti-HibK) and the amount of purified HibK386 G6PD (anti-His) following incubation without or with purified SIRT2. Levels of K386 2-hydroxyisobutyrylation were calculated from anti-HibK immunoblot intensity relative to protein amount, and normalized to HibK386 G6PD incubated without SIRT2. Bars represent the mean ± SD; n = 3. E. SIRT2 reactivates HibK386 G6PD. WT or HibK386 G6PD were co-expressed with SIRT2 in bacteria, as described in panel A. The activity of purified G6PD was measured under V max conditions and normalized to the activity of WT G6PD expressed in bacteria co-transformed with an empty vector. Bars represent the mean ± SD; n = 6. F. SIRT2-mediated de-2-hydroxyisobutyrylation of HibK288 G6PD in bacteria. The de-2-hydroxyisobutyrylation activity of SIRT2 was assessed as described in panel A. Bars represent the mean ± SD; n = 3. G. HibK62 PKM2 is a substrate of SIRT2. PKM2 was co-expressed with SIRT2 in bacteria, and 2-hydroxyisobutyrylation levels were evaluated as described in panel A. Values are displayed relative to the 2-hydroxyisobutyrylation level of PKM2 expressed in bacteria co-transformed with an empty vector. Bars represent the mean ± SD; n = 3. H, I. SIRT1- and SIRT2-mediated deacetylation of AcK386 G6PD in bacteria (H) and mammalian cells (I). Levels of K386 acetylation were determined using anti-AcK antibody as described in panels A and C. Bars represent the mean ± SD; n = 3. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test (A, B, E, G, H, and I) or t-test (C, D & F).

Article Snippet: Briefly, the DNA fragment encoding human G6PD (Gift from Xiaolu Yang Addgene plasmid # 41521; http://n2t.net/addgene:41521 ) with a C-terminal 6 × His tag was subcloned into a pCDF-Duet1 plasmid that contains the U25C mutant of PylT under the control of a constitutive lpp promoter .

Techniques: Bacteria, Expressing, Western Blot, Transformation Assay, Plasmid Preparation, Activity Assay, Cell Culture, Immunoprecipitation, Transfection, In Vitro, Purification, Incubation, Analysis